Genomic profiling of breast cancers
- 1 February 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 27 (1) , 34-39
Abstract
Purpose of review To describe recent advances in the application of advanced genomic technologies towards the identification of biomarkers of prognosis and treatment response in breast cancer. Recent findings Advances in high-throughput genomic profiling such as massively parallel sequencing have enabled researchers to catalogue the spectrum of somatic alterations in breast cancers. These tools also hold promise for precision medicine through accurate patient prognostication, stratification, and the dynamic monitoring of treatment response. For example, recent efforts have defined robust molecular subgroups of breast cancer and novel subtype-specific oncogenes. In addition, previously unappreciated activating mutations in human epidermal growth factor receptor 2 have been reported, suggesting new therapeutic opportunities. Genomic profiling of cell-free tumor DNA and circulating tumor cells has been used to monitor disease burden and the emergence of resistance, and such ‘liquid biopsy’ approaches may facilitate the early, noninvasive detection of aggressive disease. Finally, single-cell genomics is coming of age and will contribute to an understanding of breast cancer evolutionary dynamics. Summary Here, we highlight recent studies that employ high-throughput genomic technologies in an effort to elucidate breast cancer biology, discover new therapeutic targets, improve prognostication and stratification, and discuss the implications for precision cancer medicine.Keywords
This publication has 42 references indexed in Scilit:
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient dataThe Lancet Oncology, 2014
- Genetic and Phenotypic Diversity in Breast Tumor MetastasesCancer Research, 2014
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Implications of intratumour heterogeneity for treatment stratificationThe Journal of Pathology, 2013
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancyNature Genetics, 2013
- The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell CarcinomaThe American Journal of Pathology, 2013
- The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomasThe Journal of Pathology, 2011
- Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer PatientsScience Translational Medicine, 2010